Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H25ClFN7O |
| Molecular Weight | 469.942 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(NC2=NN3C(CC4=C(F)C=C(Cl)C=C4)=C(C)N=C3C(CN5CCOCC5)=C2)=NN1
InChI
InChIKey=SQSZANZGUXWJEA-UHFFFAOYSA-N
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
| Molecular Formula | C23H25ClFN7O |
| Molecular Weight | 469.942 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.pharmacodia.com/yaodu/html/v1/chemicals/6eab78f10219a83895b2e2d71dc0656e.html | https://www.ncbi.nlm.nih.gov/pubmed/23317159 | https://www.ncbi.nlm.nih.gov/pubmed/22227528
Curator's Comment: description was created based on several sources, including:
http://www.pharmacodia.com/yaodu/html/v1/chemicals/6eab78f10219a83895b2e2d71dc0656e.html | https://www.ncbi.nlm.nih.gov/pubmed/23317159 | https://www.ncbi.nlm.nih.gov/pubmed/22227528
An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. Gandotinib is in phase II clinical trials by Lilly for the treatment of myeloproliferative disorders.
Originator
Approval Year
Sample Use Guides
120 mg administered once daily for 6 cycles (168 days).
Route of Administration:
Oral
LY2784544 effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55 nM, respectively). In comparison, LY2784544 was much less potent at inhibiting interleukin-3-stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50=1183 and 1309 nM, respectively).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:52:34 UTC 2023
by
admin
on
Sat Dec 16 15:52:34 UTC 2023
|
| Record UNII |
ANC71R916O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
334211
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
||
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2107823
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
SUB128915
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
ANC71R916O
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
Gandotinib
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
ZZ-54
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
DB13040
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
100000155073
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
C116857
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
9695
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
DTXSID20153789
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
46213929
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY | |||
|
1229236-86-5
Created by
admin on Sat Dec 16 15:52:34 UTC 2023 , Edited by admin on Sat Dec 16 15:52:34 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
KI (nM) as determined in a kinetic ATP-based mechanism of action assay;
COMPETITIVE INHIBITOR
Ki
|
||
|
TARGET->WEAK INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
Biochemical measurement of JAK inhibition; Used JAK LanthaScreen Kinase assay.
COMPETITIVE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
Cellular assay; EPO TF-1 JAK2; Used Cellomics detection format.
COMPETITIVE INHIBITOR
IC50
|
||
|
|
TARGET -> INHIBITOR | |||
|
TARGET->WEAK INHIBITOR |
cellular assay;IL-2 NK-92 JAK3/JAK1; Used Cellomics detection format.
COMPETITIVE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
Cell proliferation assay
COMPETITIVE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
pSTAT5 AlphaScreen assay
COMPETITIVE INHIBITOR
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
